Clinical Trial Update: Uproleselan (GMI-1271) for GI Toxicity Prophylaxis During Melphalan-Conditioned Autologous Hematopoietic Cell Transplantation (Auto-HCT) for Multiple Myeloma (MM) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating Uproleselan (GMI-1271) for prophylaxis of GI toxicity during melphalan-conditioned autologous stem cell transplantation…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Uproleselan (GMI-1271) (uproleselan)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2023-12-15